IS2011B - Efnasamband til lækninga á krabbameini - Google Patents

Efnasamband til lækninga á krabbameini

Info

Publication number
IS2011B
IS2011B IS4434A IS4434A IS2011B IS 2011 B IS2011 B IS 2011B IS 4434 A IS4434 A IS 4434A IS 4434 A IS4434 A IS 4434A IS 2011 B IS2011 B IS 2011B
Authority
IS
Iceland
Prior art keywords
cancer
compound
treatment
Prior art date
Application number
IS4434A
Other languages
English (en)
Other versions
IS4434A (is
Inventor
K. Chu Chung
Cheng Yung-Chi
Original Assignee
University Of Georgia Research Foundation, Inc.
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/301,298 external-priority patent/US5817667A/en
Application filed by University Of Georgia Research Foundation, Inc., Yale University filed Critical University Of Georgia Research Foundation, Inc.
Publication of IS4434A publication Critical patent/IS4434A/is
Publication of IS2011B publication Critical patent/IS2011B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
IS4434A 1994-09-06 1997-03-04 Efnasamband til lækninga á krabbameini IS2011B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/301,298 US5817667A (en) 1991-04-17 1994-09-06 Compounds and methods for the treatment of cancer
US39063395A 1995-02-17 1995-02-17
PCT/US1995/011464 WO1996007413A1 (en) 1994-09-06 1995-09-05 Compounds and methods for the treatment of cancer

Publications (2)

Publication Number Publication Date
IS4434A IS4434A (is) 1997-03-04
IS2011B true IS2011B (is) 2005-05-13

Family

ID=26972285

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4434A IS2011B (is) 1994-09-06 1997-03-04 Efnasamband til lækninga á krabbameini

Country Status (31)

Country Link
US (3) US6063787A (is)
EP (2) EP0781136B1 (is)
JP (1) JP3979662B2 (is)
KR (1) KR100374477B1 (is)
CN (3) CN1111409C (is)
AP (1) AP783A (is)
AT (1) ATE267015T1 (is)
AU (1) AU704977B2 (is)
BG (1) BG63122B1 (is)
BR (1) BR9508886A (is)
CA (1) CA2199117C (is)
CZ (1) CZ297873B6 (is)
DE (1) DE69533066T2 (is)
DK (1) DK0781136T3 (is)
ES (1) ES2219666T3 (is)
FI (1) FI970918A7 (is)
HU (1) HUT77172A (is)
IL (1) IL115156A (is)
IS (1) IS2011B (is)
MY (1) MY121548A (is)
NO (1) NO313268B1 (is)
NZ (1) NZ335013A (is)
OA (1) OA10473A (is)
PL (2) PL188359B1 (is)
PT (1) PT781136E (is)
RO (1) RO118748B1 (is)
RU (1) RU2168995C2 (is)
SI (1) SI0781136T1 (is)
SK (1) SK284564B6 (is)
WO (1) WO1996007413A1 (is)
ZA (1) ZA957483B (is)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US6346627B1 (en) * 1990-02-01 2002-02-12 Emory University Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
CA2298681C (en) 1997-08-08 2008-07-08 Newbiotics, Inc. Methods and compositions for overcoming resistance to biologic and chemotherapy
JP2002500880A (ja) 1998-01-23 2002-01-15 ニューバイオティックス インコーポレイテッド 酵素に触媒される治療剤
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
MXPA00008348A (es) 1998-02-25 2005-07-15 Univ Emory 2-fluronucleosidos.
AU2004201676B2 (en) * 1999-03-29 2006-03-09 University Of Georgia Research Foundation, Inc. Methods of treating leukemia
BR0009378A (pt) 1999-03-29 2002-01-08 Shire Biochem Inc Métodos de tratamento de leucemia
US6653318B1 (en) 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
CA2385349A1 (en) 1999-09-24 2001-04-05 Francis J. Giles Method for the treatment or prevention of viral infection using nucleoside analogues
EP1225899A2 (en) 1999-11-04 2002-07-31 Virochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
EP1600452A3 (en) 1999-11-12 2008-09-10 Pharmasset, Inc. Synthesis of 2'-deoxy-L-nucleosides
US20030013660A1 (en) * 2000-10-13 2003-01-16 Shire Biochem Inc. Dioxolane analogs for improved inter-cellular delivery
CA2441350A1 (en) 2001-01-19 2002-07-25 Newbiotics, Inc. Methods to treat autoimmune and inflammatory conditions
CN1744902B (zh) * 2001-03-23 2010-05-26 希拉加拿大股份有限公司 治疗癌症的药物组合
KR20040018341A (ko) 2001-03-23 2004-03-03 샤이어 바이오켐 인코포레이티드 암치료용 약제 조성물
WO2002078678A2 (en) * 2001-03-30 2002-10-10 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
JP2005512984A (ja) * 2001-11-02 2005-05-12 シャイアー バイオケム インコーポレイテッド ジオキソランヌクレオシド類似体を含む白血病の治療のための医薬組成物
RU2302861C3 (ru) * 2001-11-19 2017-04-14 Медигене Аг Лекарственное средство для лечения вирусных кожных и опухолевых заболеваний
CA2462070C (en) 2002-06-21 2012-03-20 Lg Electronics Inc. Recording medium having data structure for managing reproduction of video data recorded thereon
EP1516329A4 (en) 2002-06-21 2009-07-15 Lg Electronics Inc RECORDING MEDIUM WITH A DATA STRUCTURE FOR MANAGING THE REPRODUCTION OF RECORDED VIDEO DATA
KR20040000290A (ko) 2002-06-24 2004-01-03 엘지전자 주식회사 고밀도 광디스크의 멀티 경로 데이터 스트림 관리방법
JP4399568B2 (ja) 2002-06-24 2010-01-20 エルジー エレクトロニクス インコーポレイティド 多重タイトルビデオデータの再生を管理するためのデータ構造を有する記録媒体とそれによる記録及び再生方法と装置
EP1518240B1 (en) 2002-06-28 2014-05-07 LG Electronics, Inc. Recording medium having data structure for managing recording and reproduction of multiple path data recorded thereon and recording and reproducing methods and apparatus
DE60313344T2 (de) * 2002-09-24 2008-01-03 Novartis Ag Verwendung von 4-pyridylmethyl-phthalazin-derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen
JP4431043B2 (ja) 2002-10-14 2010-03-10 エルジー エレクトロニクス インコーポレイティド 記録された複数のオーディオストリームの再生を管理するためのデータ構造を有する光ディスク、それによる記録及び再生方法及び装置
WO2004036578A1 (en) 2002-10-15 2004-04-29 Lg Electronics Inc. Recording medium having data structure for managing reproduction of multiple graphics streams recorded thereon and recording and reproducing methods and apparatuses
US7720356B2 (en) 2002-11-12 2010-05-18 Lg Electronics Inc Recording medium having data structure for managing reproduction of multiple reproduction path video data recorded thereon and recording and reproducing methods and apparatuses
JP4242839B2 (ja) 2002-11-12 2009-03-25 エルジー エレクトロニクス インコーポレーテッド 記録された多重再生経路ビデオデータの再生を管理するためのデータ構造を有する記録媒体とそれによる記録及び再生方法及び装置
US7664372B2 (en) 2002-11-20 2010-02-16 Lg Electronics Inc. Recording medium having data structure for managing reproduction of multiple component data recorded thereon and recording and reproducing methods and apparatuses
US7606463B2 (en) 2003-02-24 2009-10-20 Lg Electronics, Inc. Recording medium having data structure for managing playback control and recording and reproducing methods and apparatuses
US7693394B2 (en) 2003-02-26 2010-04-06 Lg Electronics Inc. Recording medium having data structure for managing reproduction of data streams recorded thereon and recording and reproducing methods and apparatuses
US7809775B2 (en) 2003-02-27 2010-10-05 Lg Electronics, Inc. Recording medium having data structure for managing playback control recorded thereon and recording and reproducing methods and apparatuses
EP1604356A4 (en) 2003-02-28 2009-12-16 Lg Electronics Inc RECORD MEDIUM WITH A DATA STRUCTURE FOR MANAGING THE RANDOM / SHUFFLE PLAYBACK OF RECORDED VIDEO DATA, AND METHOD AND DEVICES FOR RECORDING AND PLAYING
US7620301B2 (en) 2003-04-04 2009-11-17 Lg Electronics Inc. System and method for resuming playback
ES2391561T3 (es) 2003-10-09 2012-11-27 Medigene Ag Uso de un polifenol para el tratamiento de una lesión cancerosa o pre-cancerosa de la piel
US7879816B2 (en) * 2005-06-07 2011-02-01 Yale University Methods of treating cancer and other conditions or disease states using LFMAU and LDT
WO2007067364A2 (en) * 2005-12-02 2007-06-14 Yale University Methods of treating cancer and other conditions or disease states using l-cytosine nucleoside analogs
NO324263B1 (no) * 2005-12-08 2007-09-17 Clavis Pharma Asa Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser
KR20090057050A (ko) * 2006-09-01 2009-06-03 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 암치료를 위한 트록사시타빈 전구약물
RU2322243C1 (ru) * 2006-10-20 2008-04-20 Наталья Юрьевна Костюкова Фармацевтическая композиция для лечения поражений роговицы
CN102406649A (zh) * 2011-11-15 2012-04-11 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
CN103720693A (zh) * 2011-11-15 2014-04-16 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
JP7110203B2 (ja) * 2016-12-28 2022-08-01 トランジェーヌ 腫瘍溶解性ウイルスおよび治療用分子
SG10201708886RA (en) * 2017-10-30 2019-05-30 Xylonix Ip Holdings Pte Ltd α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
FI87783C (fi) * 1985-05-15 1993-02-25 Wellcome Found Foerfarande foer framstaellning av terapeutiskt anvaendbara 2',3'-dideoxinukleosider
WO1987001284A1 (en) * 1985-08-26 1987-03-12 United States Of America, Represented By The Unite Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2',3'-dideoxynosine, 2',3'-dideoxyguanosine, or 2',3'-dideoxyadenosine
US4879277A (en) * 1985-08-26 1989-11-07 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions and methods
DE3650741T2 (de) * 1985-09-17 2000-10-12 The Wellcome Foundation Ltd., Greenford Kombination therapeutische Nukleoside mit weiteren therapeutisch wirksamen Komponenten.
IN164556B (is) * 1986-03-06 1989-04-08 Takeda Chemical Industries Ltd
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
FR2601385B1 (fr) * 1986-07-09 1989-09-29 Sucre Rech & Dev Procede de preparation a partir de saccharose d'un melange de sucres a haute teneur en isomaltose par voie enzymatique et produits obtenus
US4963533A (en) * 1986-10-24 1990-10-16 Stichting Rega Vzw (Rega) Therapeutic application of dideoxycytidinene
US5215971A (en) * 1986-12-19 1993-06-01 Medivir Ab Antiviral pharmaceutical composition comprising 5-substituted pyrimidine nucleosides
EP0342203B1 (en) * 1987-03-24 1994-07-06 Nycomed Imaging As 2',3' dideoxyribofuranoxide derivatives
US5185437A (en) * 1987-04-09 1993-02-09 Burroughs Wellcome Co. Therapeutic nucleosides
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US4900828A (en) * 1988-05-12 1990-02-13 Hoffmann-Laroche Inc. Intermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidine
SE8802687D0 (sv) * 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
EP0375329B1 (en) * 1988-12-19 1995-05-31 The Wellcome Foundation Limited Antiviral pyrimidine and purine compounds, process for their preparation and pharmaceutical compositions containing them
UA45942A (uk) * 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
US5059690A (en) * 1990-03-01 1991-10-22 E. R. Squibb & Sons, Inc. Purinyl tetrahydrofurans
US5071983A (en) * 1989-10-06 1991-12-10 Burroughs Wellcome Co. Therapeutic nucleosides
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
IE904378A1 (en) * 1989-12-20 1991-07-03 Abbott Lab Analogs of oxetanyl purines and pyrimidines
US5700937A (en) * 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5527782A (en) * 1990-03-13 1996-06-18 Acic (Canada) Inc. 5-halo-2,3'-O-cyclocytidines
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
WO1992010496A1 (en) * 1990-12-05 1992-06-25 University Of Georgia Research Foundation, Inc. ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
EP1808434A3 (en) * 1991-03-06 2008-04-02 Emory University Use of 5-fluoro-2'-deoxy-3'-thiacytidine fo the treatment of hepatitis B
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9226927D0 (en) 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
WO1995018137A1 (en) * 1993-12-30 1995-07-06 Genta Incorporated Improved process for the purification of oligomers
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5971983A (en) * 1997-05-09 1999-10-26 The Regents Of The University Of California Tissue ablation device and method of use

Also Published As

Publication number Publication date
RO118748B1 (ro) 2003-10-30
FI970918A0 (fi) 1997-03-04
CZ63397A3 (en) 1997-07-16
BR9508886A (pt) 1997-12-30
HUT77172A (hu) 1998-03-02
US8076347B2 (en) 2011-12-13
OA10473A (en) 2002-04-08
SK284564B6 (sk) 2005-06-02
CA2199117A1 (en) 1996-03-14
CZ297873B6 (cs) 2007-04-18
NO313268B1 (no) 2002-09-09
PL189288B1 (pl) 2005-07-29
JPH10506385A (ja) 1998-06-23
CN1448142A (zh) 2003-10-15
NZ335013A (en) 2000-07-28
PL188359B1 (pl) 2005-01-31
BG63122B1 (bg) 2001-04-30
MY121548A (en) 2006-02-28
US6063787A (en) 2000-05-16
FI970918L (fi) 1997-05-02
CN1827108A (zh) 2006-09-06
DK0781136T3 (da) 2004-08-02
EP0781136B1 (en) 2004-05-19
BG101284A (bg) 1998-03-31
CN1111409C (zh) 2003-06-18
US20050261320A1 (en) 2005-11-24
SI0781136T1 (en) 2004-08-31
IL115156A (en) 2000-07-16
ES2219666T3 (es) 2004-12-01
CN1251680C (zh) 2006-04-19
KR100374477B1 (ko) 2003-06-19
IS4434A (is) 1997-03-04
CA2199117C (en) 2006-04-11
KR970705393A (ko) 1997-10-09
NO971015D0 (no) 1997-03-05
AU704977B2 (en) 1999-05-13
EP0781136A1 (en) 1997-07-02
US7262213B2 (en) 2007-08-28
EP0781136A4 (en) 1999-06-23
PT781136E (pt) 2004-09-30
JP3979662B2 (ja) 2007-09-19
ZA957483B (en) 1997-06-06
AU3586295A (en) 1996-03-27
DE69533066T2 (de) 2005-06-02
EP1468687A1 (en) 2004-10-20
WO1996007413A1 (en) 1996-03-14
DE69533066D1 (de) 2004-06-24
PL318971A1 (en) 1997-07-21
SK28197A3 (en) 1997-09-10
IL115156A0 (en) 1995-12-31
AP783A (en) 1999-11-17
RU2168995C2 (ru) 2001-06-20
FI970918A7 (fi) 1997-05-02
CN1160351A (zh) 1997-09-24
ATE267015T1 (de) 2004-06-15
US20080171758A1 (en) 2008-07-17
AP9700939A0 (en) 1997-04-30
NO971015L (no) 1997-03-05

Similar Documents

Publication Publication Date Title
IS4434A (is) Efnasamband til lækninga á krabbameini
CY2013020I1 (el) Η χρηση μιας ενωσης ινγκενανης για την κατασκευη ενος φαρμακου για την θεραπεια του καρκινου
DK0769017T3 (da) Terapeutiske forbindelser
ATE192157T1 (de) Therapeutisch verwendbare spiro-azabicyclische verbindungen
FI971260A7 (fi) 1-asyyli-4-alifatyyliaminopiperidiiniyhdisteet
FI970995L (fi) Farmaseuttisia yhdisteitä
FI971018L (fi) Farmaseuttisia yhdisteitä
BR9509760A (pt) Composto
NO941142D0 (no) Tumor-nekrosefaktormuteiner
FI971568A0 (fi) Menetelmä resistenttien kasvainten hoitamiseksi
FI972484L (fi) Karsinooman hoito
FI954243A7 (fi) Farmaseuttiset yhdisteet
FI972683L (fi) Kemiallisia yhdisteitä
ID17723A (id) Senyawa untuk pengobatan
FI960658A7 (fi) Uudet bis-naftalimidit syövän hoitamiseksi
NO983090D0 (no) Terapeutiske forbindelser
FI970151A0 (fi) Viruksenvastaisesti vaikuttavia difluoristatoniyhdisteitä
NO972257D0 (no) 18-nor-vitamin D-forbindelser
FI971971A7 (fi) Pyridatsinokinoliiniyhdisteitä
DE59804807D1 (de) Pi-komplex-verbindungen
RU95102269A (ru) Препарат для лечения первичного рака печени
KR950031549U (ko) 매립형 콘센트
LV11594A (lv) Arstniecisks lidzeklis psoriazes arstesanai
KR950029395U (ko) 장제용 위패케이스
UA25833C2 (uk) Засіб для лікуваhhя мелаhомобластом